SSY Group Limited (02005.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.5x

Market Cap

HKD 8.06B

MomentumView details →

1D Return

−0.18%

YTD Return

−3.53%

RSI (14)

75.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.5x

Market Cap

HKD 8.06B

RSI (14)

75.9

MomentumView details →

1D Return

−0.18%

YTD Return

−3.53%

ProfitabilityView details →

Gross Margin

41.38%

Net Margin

13.02%

EBITDA Margin

25.75%

ROE (TTM)

14.95%

ROA (TTM)

8.66%

Asset Turnover

0.68x

GrowthView details →

Revenue YoY

−30.17%

EPS YoY

−53.45%

FCF YoY

−35.98%

Revenue CAGR 3Y

−13.49%

EPS CAGR 3Y

−25.05%

EBITDA YoY

−42.23%

EarningsView details →

EPS (Actual)

HKD 0.11

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

−0.09%

Capital & dividendView details →

Debt/Equity

0.52x

Current Ratio

1.87x

Quick Ratio

1.43x

Div Yield

2.93%

Div Rate

HKD 0.08

Div Growth 1Y

−79.31%

Financials snapshotView financials →

Revenue (TTM)

8.96B

Net Income (TTM)

1.17B

Op. CF (TTM)

854.01M

Next earningsMar 26, 2027 →

Latest newsMore news →

SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.3d ago

SSY Group Limited reported interim results for the six months ended June 2026, with net profit of HK$320 million, up 13% year-on-year, and revenue of HK$2.361 billion, up 9.9%.10d ago

Similar companies

华北制药600812.SH 太极集团600129.SH 上海谊众688091.SH 汇宇制药-W688553.SH 鲁抗医药600789.SH 复旦张江688505.SH Find similar companies →

Latest newsMore news →

SSY Group announced that its Diltiazem Hydrochloride Tablets (30mg) received approval from China's National Medical Products Administration for passing the consistency evaluation of generic drug quality and efficacy, making it the third domestic company to obtain such approval.3d ago SSY Group Limited reported interim results for the six months ended June 2026, with net profit of HK$320 million, up 13% year-on-year, and revenue of HK$2.361 billion, up 9.9%.10d ago SSY Group Limited received a drug production registration certificate from China's National Medical Products Administration for its Vitamin K1 injection (1ml:10mg), a Class 3 chemical drug deemed equivalent to generic consistency evaluation.16d ago